295 related articles for article (PubMed ID: 16703293)
1. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
3. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
[TBL] [Abstract][Full Text] [Related]
6. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
8. Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients.
Oette M; Kurowski M; Feldt T; Kroidl A; Sagir A; Vogt C; Wettstein M; Häussinger D
J Antimicrob Chemother; 2005 Aug; 56(2):416-9. PubMed ID: 15983027
[TBL] [Abstract][Full Text] [Related]
9. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
10. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
[TBL] [Abstract][Full Text] [Related]
11. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.
Prasithsirikul W; Bunnag P
J Med Assoc Thai; 2004 Feb; 87(2):166-72. PubMed ID: 15061300
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy.
Bickel M; Zangos S; Jacobi V; Lutz T; Knecht G; Goebel F; Staszewski S; Klauke S
HIV Med; 2006 Sep; 7(6):397-403. PubMed ID: 16903985
[TBL] [Abstract][Full Text] [Related]
14. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
[TBL] [Abstract][Full Text] [Related]
15. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
[TBL] [Abstract][Full Text] [Related]
16. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
Martínez E; Domingo P; Ribera E; Milinkovic A; Arroyo JA; Conget I; Pérez-Cuevas JB; Casamitjana R; de Lazzari E; Bianchi L; Montserrat E; Roca M; Burgos R; Arnaiz JA; Gatell JM
Antivir Ther; 2003 Oct; 8(5):403-10. PubMed ID: 14640387
[TBL] [Abstract][Full Text] [Related]
17. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
18. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
Andersen O; Haugaard SB; Flyvbjerg A; Andersen UB; Ørskov H; Madsbad S; Nielsen JO; Iversen J
Eur J Clin Invest; 2004 Aug; 34(8):561-8. PubMed ID: 15305891
[TBL] [Abstract][Full Text] [Related]
19. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic therapy for HIV-associated lipodystrophy.
Benavides S; Nahata MC
Ann Pharmacother; 2004 Mar; 38(3):448-57. PubMed ID: 14755064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
